HighTower Advisors
DNLI icon

HighTower Advisors’s Denali Therapeutics DNLI Stock Holding History

HighTower Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283K Sell
11,020
-951
-8% -$19.5K ﹤0.01% 3262
2026
Q1 		$230K Buy
11,971
+214
+2% +$4.26K ﹤0.01% 3380
2025
Q4 		$194K Sell
11,757
-9,565
-45% -$161K ﹤0.01% 3389
2025
Q3 		$310K Sell
21,322
-1,211
-5% -$17.4K ﹤0.01% 3016
2025
Q2 		$315K Sell
22,533
-1,070
-5% -$15.1K ﹤0.01% 2889
2025
Q1 		$321K Sell
23,603
-2,535
-10% -$48.6K ﹤0.01% 2803
2024
Q4 		$533K Sell
26,138
-11,189
-30% -$286K ﹤0.01% 2429
2024
Q3 		$1.09M Sell
37,327
-587
-2% -$14.6K ﹤0.01% 1890
2024
Q2 		$884K Sell
37,914
-1,306
-3% -$25.1K ﹤0.01% 1919
2024
Q1 		$813K Sell
39,220
-413
-1% -$7.76K ﹤0.01% 1937
2023
Q4 		$858K Sell
39,633
-14,699
-27% -$291K ﹤0.01% 1925
2023
Q3 		$1.13M Sell
54,332
-185
-0.3% -$4.69K ﹤0.01% 1695
2023
Q2 		$1.61M Buy
54,517
+2,813
+5% +$79.1K ﹤0.01% 1485
2023
Q1 		$1.19M Buy
51,704
+29,495
+133% +$812K ﹤0.01% 1571
2022
Q4 		$623K Buy
22,209
+3,386
+18% +$101K ﹤0.01% 1973
2022
Q3 		$573K Buy
+18,823
New +$612K ﹤0.01% 1925

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

HighTower Advisors's DNLI Position: Q2 2026 in Review

HighTower Advisors reduced its Denali Therapeutics (DNLI) stake by 7.9% in Q2 2026, selling an estimated $19.5K and leaving 11,020 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #3262.

HighTower Advisors first reported a position in DNLI in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.61M in Q2 2023. 112 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • HighTower Advisors held 11,020 shares of Denali Therapeutics worth $283K as of Q2 2026.
  • HighTower Advisors sold 951 Denali Therapeutics shares in Q2 2026, an estimated $19.5K.
  • Denali Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3262 holding.
  • HighTower Advisors first reported a position in Denali Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • HighTower Advisors's Denali Therapeutics position peaked at $1.61M in Q2 2023.
  • 112 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.